{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:01Z","timestamp":1747181101861,"version":"3.40.5"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The mortality and recurrence of patients with cancer is of high prevalence. Long non-coding RNA (lncRNA) forkhead box P4 antisense RNA 1 (FOXP4-AS1) is a promising lncRNA. There is increasing evidence that lncRNA FOXP4-AS1 is abnormally expressed in various tumors and is associated with cancer prognosis. This study was designed to identify the prognostic value of lncRNA FOXP4-AS1 in human malignancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched electronic databases up to April 29, 2022, including PubMed, Cochrane Library, Embase, MEDLINE, and Web of Science. Eligible studies that evaluated the clinicopathological and prognostic role of lncRNA FOXP4-AS1 in patients with malignant tumors were included. The pooled odds ratios (ORs) and the hazard ratios (HRs) were calculated to assess the role of lncRNA FOXP4-AS1 using Stata\/SE 16.1 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 6 studies on cancer patients were included in the present meta-analysis. The combined results revealed that high expression of lncRNA FOXP4-AS1 was significantly associated with unfavorable overall survival (OS) (HR = 1.99, 95% confidence interval [CI]: 1.65\u20132.39, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .00001), and poor disease-free survival (DFS) (HR = 1.81, 95% CI: 1.54\u20132.13, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .00001) in a variety of cancers. In additional, the increase in lncRNA FOXP4-AS1 expression was also correlated with tumor size ((larger vs smaller) (OR = 3.16, 95% CI: 2.12\u20134.71, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .00001), alpha-fetoprotein (\u2265400 vs &lt;400) (OR = 3.81, 95%CI: 2.38\u20136.11, <jats:italic toggle=\"yes\">P<\/jats:italic> = .83), lymph node metastasis (positive vs negative) (OR = 2.93, 95%CI: 1.51\u20135.68, <jats:italic toggle=\"yes\">P<\/jats:italic> = .001), and age (younger vs older) (OR = 2.06, 95% CI: 1.41\u20133.00, <jats:italic toggle=\"yes\">P<\/jats:italic> = .00002) in patients with cancer. Furthermore, analysis results using The Cancer Genome Atlas (TCGA) dataset showed that the expression level of lncRNA FOXP4-AS1 was higher in most tumor tissues than in the corresponding normal tissues, which predicted a worse prognosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In this meta-analysis, we demonstrate that high lncRNA FOXP4-AS1 expression may become a potential marker to predict cancer prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000031439","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T19:00:43Z","timestamp":1666638043000},"page":"e31439","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The clinical prognostic value of lncRNA FOXP4-AS1 in cancer patients: A meta-analysis and bioinformatics analysis based on TCGA datasets"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3571-4084","authenticated-orcid":false,"given":"Qiang","family":"Shu","sequence":"first","affiliation":[{"name":"Department of Hepatic-Biliary-Pancreatic Surgery, The Neijiang First People\u2019s Hospital affiliated to Chongqing Medical University, Neijiang City, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hospital Infection Management, The Neijiang Hospital of Traditional Chinese Medicine, Neijiang City, Sichuan Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jushu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatic-Biliary-Pancreatic Surgery, The Neijiang First People\u2019s Hospital affiliated to Chongqing Medical University, Neijiang City, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinggang","family":"Mou","sequence":"additional","affiliation":[{"name":"Department of Hepatic-Biliary-Pancreatic Surgery, The Neijiang First People\u2019s Hospital affiliated to Chongqing Medical University, Neijiang City, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hepatic-Biliary-Pancreatic Surgery, The Neijiang First People\u2019s Hospital affiliated to Chongqing Medical University, Neijiang City, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology.","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J Epidemiol Glob Health"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-biochem-051410-092902","article-title":"Genome regulation by long noncoding RNAs.","volume":"81","author":"Rinn","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nature10887","article-title":"Modular regulatory principles of large non-coding RNAs.","volume":"482","author":"Guttman","year":"2012","journal-title":"Nature"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3390\/ijms17101617","article-title":"Long noncoding RNA lncCAMTA1 promotes proliferation and cancer stem cell-like properties of liver cancer by inhibiting CAMTA1.","volume":"17","author":"Ding","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.biopha.2018.02.123","article-title":"Long non-coding RNA Linc00675 suppresses cell proliferation and metastasis in colorectal cancer via acting on miR-942 and Wnt\/\u03b2-catenin signaling.","volume":"101","author":"Shan","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"BSR20181039","DOI":"10.1042\/BSR20181039","article-title":"LINC00675 is a prognostic factor and regulates cell proliferation, migration and invasion in glioma.","volume":"38","author":"Li","year":"2018","journal-title":"Biosci Rep"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.biopha.2018.07.101","article-title":"Long non-coding RNA NORAD upregulate SIP1 expression to promote cell proliferation and invasion in cervical cancer.","volume":"106","author":"Huo","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41419-019-1740-9","article-title":"LINC81507 act as a competing endogenous RNA of miR-199b-5p to facilitate NSCLC proliferation and metastasis via regulating the CAV1\/STAT3 pathway.","volume":"10","author":"Peng","year":"2019","journal-title":"Cell Death Dis"},{"key":"R10-20250504","first-page":"167","article-title":"The association of HOTAIR expression with clinicopathological features and prognosis in gastric cancer patients.","volume":"58","author":"Liu","year":"2016","journal-title":"Panminerva Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"40620","DOI":"10.18632\/oncotarget.16534","article-title":"The prognostic significance of UCA1 for predicting clinical outcome in patients with digestive system malignancies.","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.2147\/OTT.S220923","article-title":"Upregulation of long non-coding RNA FOXP4-AS1 and its regulatory network in hepatocellular carcinoma.","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"R13-20250504","article-title":"Identification of a prognostic colorectal cancer model including LncRNA FOXP4-AS1 and LncRNA BBOX1-AS1 based on bioinformatics analysis.","author":"Shi","year":"2021","journal-title":"Cancer Biother Radiopharm"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13205-020-02593-8","article-title":"LncRNA FOXP4-AS1 serves as a biomarker for nasopharyngeal carcinoma diagnosis and prognosis.","volume":"11","author":"Yao","year":"2021","journal-title":"3 Biotech"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2147\/OTT.S241818","article-title":"LncRNA FOXP4-AS1 is involved in cervical cancer progression via regulating miR-136-5p\/CBX4 axis.","volume":"13","author":"Zhao","year":"2020","journal-title":"Onco Targets Ther"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e12312","DOI":"10.1111\/cpr.12312","article-title":"Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer.","volume":"50","author":"Li","year":"2017","journal-title":"Cell Prolif"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis.","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e001368","DOI":"10.1136\/bmjopen-2012-001368","article-title":"Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales.","volume":"2","author":"Oremus","year":"2012","journal-title":"BMJ Open"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"8850656","DOI":"10.1155\/2021\/8850656","article-title":"Long noncoding RNA FOXP4-AS1 predicts unfavourable prognosis and regulates proliferation and invasion in hepatocellular carcinoma.","volume":"2021","author":"Liang","year":"2021","journal-title":"Biomed Res Int"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3892\/or.2020.7897","article-title":"lncRNA FOXP4-AS1 predicts poor prognosis and accelerates the progression of mantle cell lymphoma through the miR-423-5p\/NACC1 pathway.","volume":"45","author":"Tao","year":"2021","journal-title":"Oncol Rep"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bbrc.2018.05.198","article-title":"FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2.","volume":"502","author":"Yang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R22-20250504","first-page":"8008","article-title":"Long non-coding RNA FOXP4-AS1 acts as an adverse prognostic factor and regulates proliferation and apoptosis in nasopharyngeal carcinoma.","volume":"24","author":"Zhong","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41419-019-1699-6","article-title":"LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4.","volume":"10","author":"Wu","year":"2019","journal-title":"Cell Death Dis"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"773864","DOI":"10.3389\/fonc.2021.773864","article-title":"LncRNA FOXP4-AS1 promotes the progression of esophageal squamous cell carcinoma by interacting with MLL2\/H3K4me3 to upregulate FOXP4.","volume":"11","author":"Niu","year":"2021","journal-title":"Front Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/cam4.2818","article-title":"Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1093\/brain\/awv287","article-title":"c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.","volume":"138","author":"Luo","year":"2015","journal-title":"Brain"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trsl.2020.10.011","article-title":"Oncogene or tumor suppressor? Long noncoding RNAs role in patient\u2019s prognosis varies depending on disease type.","volume":"230","author":"Huang","year":"2021","journal-title":"Transl Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:42:36Z","timestamp":1746333756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":27,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031439","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}